

Mucopolysaccharidosis Vi

[View the current Mucopolysaccharidosis Vi InDepth page on BioPortfolio.com](#) ([PDF](#))

(http://www.bioportfolio.com/indepth/Mucopolysaccharidosis_Vi.html) - Regularly Updated.

Recent Publications on Mucopolysaccharidosis Vi:



- [Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen.](#)
All MPS-VI cats treated thus far with weekly intravenous enzyme...10th November, 2009
Lysosomal Diseases Research Unit, SA Pathology (at Women's and Children's- Mol Genet Metab. 2009 Oct 13. ([DOI Direct Link](#))
- [A systematic review of new advances in the management of mucopolysaccharidosis VI \(Maroteaux-Lamy syndrome\): focus on galsulfase.](#)
INTRODUCTION: Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy...24th October, 2009
Department of Surgery, McMaster University, McMaster Institute of Urology,- Biologics. 2009;3:459-68. Epub 2009 Oct 12.
- [Cell-surface arylsulfatase A and B on sinusoidal endothelial cells, hepatocytes, and Kupffer cells in mammalian livers.](#)
Arylsulfatase A (ARSA) and B (ARSB) have been regarded as lysosomal...15th August, 2009
Department of Mathematical and Life Sciences, Graduate School of Science,- Med Mol Morphol. 2009 Jun;42(2):63-9. Epub 2009 Jun 18. ([DOI Direct Link](#))
- [Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis?](#)
BACKGROUND: To describe the ocular changes noted in seven patients with...15th August, 2009
Department of Ophthalmology, Johannes Gutenberg University, Mainz,- Graefes Arch Clin Exp Ophthalmol. 2009 Jul;247(7):975-80. Epub 2009 Jan ([DOI Direct Link](#))
- [Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI.](#)
BACKGROUND: Mucopolysaccharidosis VI (MPS VI) is a very rare, chronically...25th July, 2009
Institute for Innovation & Valuation in Health Care (InnoVal), Wiesbaden,- Curr Med Res Opin. 2009 May;25(5):1285-93. ([DOI Direct Link](#))
- [Lentiviral-mediated correction of MPS VI cells and gene transfer to joint tissues.](#)
Joint disease in mucopolysaccharidosis type VI (MPS VI) remains difficult...3rd July, 2009
Matrix Biology Unit, Department of Genetics, SA Pathology, Women's and- Mol Genet Metab. 2009 Jun;97(2):102-8. Epub 2009 Feb 27. ([DOI Direct Link](#))
- [Abnormal autophagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of mucopolysaccharidosis VI.](#)
ABSTRACT: BACKGROUND: Lysosomal storage diseases are characterized by...18th June, 2009
Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.- Pathogenetics. 2009 Jun 16;2(1):4. ([DOI Direct Link](#))

- [Evaluation of orofacial motricity in patients with mucopolysaccharidosis: a cross-sectional study.](#)
*OBJECTIVES: To characterize the stomatognathic system and stomatognathic...*6th June, 2009
Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.- J Pediatr (Rio J). 2009
May-Jun;85(3):254-60. ([DOI Direct Link](#))
- [Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively.](#)
*Enzyme replacement therapy for lysosomal storage disorders has made an...*25th April, 2009
Willink Biochemical Genetics Unit, Royal Manchester Children's Hospital,- J Inherit Metab Dis. 2008
Dec;31(6):733-7. Epub 2008 Oct 19. ([DOI Direct Link](#))
- [Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy.](#)
*We compared substrate reduction in patients with lysosomal storage...*15th April, 2009
Department of Haematology and BMT, Royal Manchester Children's Hospital,- J Pediatr. 2009
Apr;154(4):609-11. ([DOI Direct Link](#))
- [Enzyme replacement therapy in the home setting for mucopolysaccharidosis VI: a survey of patient characteristics and physicians' early findings in the United States.](#)
*Galsulfase, a Food and Drug Administration-approved enzyme replacement...*11th March, 2009
Division of Genetics & Metabolism, Children's National Medical Center,- J Infus Nurs. 2009
Jan-Feb;32(1):45-52. ([DOI Direct Link](#))
- [Defective cellular trafficking of missense NPR-B mutants is the major mechanism underlying acromesomelic dysplasia-type Maroteaux.](#)
*Natriuretic peptides (NPs) comprise a family of structurally related but...*4th February, 2009
Department of Pathology, United Arab Emirates University, Al-Ain, United- Hum Mol Genet. 2009 Jan
15;18(2):267-77. Epub 2008 Oct 22. ([DOI Direct Link](#))
- [Mucopolysaccharidosis VI: the Italian experience.](#)
*The current paper describes the natural history and management of...*9th January, 2009
University of Padova, Padua, Italy.- Eur J Pediatr. 2009 Oct;168(10):1203-6. Epub 2009 Jan 7. ([DOI Direct Link](#))
- [Altered olfactory epithelial structure and function in feline models of mucopolysaccharidoses I and VI.](#)
*The mucopolysaccharidoses (MPS) are a family of lysosomal storage diseases...*17th December, 2008
Monell Chemical Senses Center, Philadelphia, Pennsylvania 19104-3308, USA.- J Comp Neurol. 2008
Nov 20;511(3):360-72. ([DOI Direct Link](#))
- [Long-term follow-up of a girl with Maroteaux-Lamy syndrome after bone marrow transplantation.](#)
*BACKGROUND: Mucopolysaccharidosis type VI (MPS VI or Maroteaux-Lamy...*17th December, 2008
Department of Pediatrics, National Taiwan University Hospital and College- World J Pediatr. 2008
May;4(2):152-4. ([DOI Direct Link](#))

Mucopolysaccharidosis Vi Patents:



- 7615224- [Multiplex-bead complex for determination of lysosomal storage disorders](#)
- 6800472- [Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester .alpha.-N-acetyl glucosaminidase](#)
- 6770468- [Phosphodiester-a-GlcNAcase of the lysosomal targeting pathway](#)
- 6670194- [Rapid quantitative analysis of proteins or protein function in complex mixtures](#)

- 6670165- [Methods for producing highly phosphorylated lysosomal hydrolases](#)
- 6642038- [GlcNAc phosphotransferase of the lysosomal targeting pathway](#)
- 6537785- [Methods of treating lysosomal storage diseases](#)
- 6534300- [Methods for producing highly phosphorylated lysosomal hydrolases](#)
- 6204248- [Pharmaceutical preparations of glutathione and methods of administration thereof](#)
- 6828135- [Phosphodiester .alpha.-GlcNAcase of the lysosomal targeting pathway](#)
- 6852544- [Rapid quantitative analysis of proteins or protein function in complex mixtures](#)
- 7371366- [GlcNAc phosphotransferase of the lysosomal targeting pathway](#)
- 7135322- [Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester .alpha.-N-acetyl glucosaminidase](#)
- 7067127- [GlcNAc phosphotransferase of the lysosomal targeting pathway](#)
- 6972124- [Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme](#)
- 6905856- [Soluble GlcNAc phosphotransferase](#)
- 6896899- [Pharmaceutical preparations of glutathione and methods of administration thereof](#)
- 6866844- [Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme](#)
- 6861242- [Methods for producing highly phosphorylated lysosomal hydrolases](#)
- 4749570- [Targeting conjugates of albumin and therapeutic agents](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

